We have constructed a novel oncolytic adenovirus (Ad) vector, named VRX-011, in which the replication of the vector is targeted to cancer cells by the replacement of the wild-type Ad E4 promoter with the human telomerase reverse transcriptase (hTERT) promoter. Genes in the Ad E4 transcription unit are essential for Ad replication; therefore, VRX-011 will grow efficiently only in cells in which the hTERT promoter is active, that is, in a wide range of cancer and immortalized cells but not in most somatic cells. Consistent with these expectations, VRX-011 replicated efficiently in all cancer cell lines examined, while its growth was restricted in various primary and normal cells. VRX-011 overexpresses ADP (also known as E3-11.6K), an Ad protein required for efficient cell lysis and release of virions from cells at late stages of infection. This overexpression enhances cell-to-cell spread and could significantly increase antitumor efficacy. In a xenograft model in nude mice, both intratumoral and intravenous administration of VRX-011 effectively suppressed the growth of subcutaneous Hep3B human liver tumors. Also, intravenous delivery of VRX-011 greatly reduced the number and size of A549 human lung cancer cell nodules in a disseminated lung tumor model in nude mice. Importantly, tail vein administration of different doses of VRX-011 in C57BL/6 mice showed minimal liver toxicity. Considering its broad range of lytic replication in cancer cells, its attenuated phenotype in primary cells, its efficacy in suppressing xenografts, and its low toxicity in mouse liver, VRX-011 is a promising candidate for further evaluation as an anticancer therapeutic.
Introduction
Cancer gene therapy using genetically modified viral 'vectors' is a relatively new field of cancer research. A major goal of this research is to develop vectors that selectively kill tumor cells or inhibit their growth while at the same time sparing normal cells. Adenovirus (Ad) vectors were originally developed as viral gene transfer vectors; they exhibit natural tropism to a wide range of epithelial tissues, including cancer cells. 1 Subsequently, replicating Ad vectors designed to selectively grow and lyse tumor cells were constructed. 2, 3 Conditionally replicating Ad vectors can infect at first a portion of tumor cells, replicate in them, lyse them, and release progeny virus. These newly synthesized virions are expected to infect neighboring tumor cells and perpetuate the process until all tumor cells are lysed. Various strategies to achieve tumor-selective vector replication have been reported. 4 One way to engineer conditionally replicating Ad vectors is to place key virus genes under the regulatory control of specific promoters that are active only in appropriate target cells. Thus far, a large number of promoters have been applied to control the vector replication. 5, 6 Although most of these vectors perform well, many Ad vectors utilizing tumor-specific or tissue-specific promoters showed some activity in normal cells. 7 Also, most of these promoter-substituted Ad vectors are restricted to a certain type of cancer, and cannot be applied to a different variety of tumors.
Here, we report a vector named VRX-011 ( Figure 1c ) that can replicate effectively in a wide range of cancer cell lines and spread efficiently from cell to cell, yet its replication is restricted in normal cells. We have reported previously that upon replacement of the wild-type (wt) E4 promoter with the surfactant protein B (SPB) promoter or a synthetic b-catenin responsive element, the replication of the vector was restricted to lung or colon cancer cells, respectively. 8, 9 The E4 region encodes proteins that are essential for Ad replication; they regulate replication of viral DNA, induction of apoptosis, and host cell protein synthesis. [10] [11] [12] With VRX-011, the wt E4 promoter is replaced by the human telomerase reverse transcriptase (hTERT) promoter. hTERT is the catalytic subunit of the human telomerase enzyme, which maintains telomere length at the end of the chromosomes. About 85% of human cancers display elevated levels of telomerase activity, while telomerase activity is not detected in normal somatic cells. 13, 14 The enzyme is regulated at the transcriptional level; hTERT mRNA expression and telomerase activity are tightly associated in human cancers. 15 This opens up the possibility of using the hTERT promoter to restrict gene expression to cancer cells. Various nonreplicating Ad vectors applying the hTERT promoter to regulate anticancer therapeutic genes have been reported. [16] [17] [18] [19] [20] [21] Several oncolytic Ad vectors in which the hTERT promoter regulates the expression of the E1A [22] [23] [24] [25] [26] [27] [28] or E4 29,30 genes have also been described.
Besides having the wt E4 promoter replaced, VRX-011 overexpresses the adenovirus death protein (ADP). ADP is expressed at very late times during Ad infection and promotes the lysis of the infected cell, thus facilitating virus release.
31,32 Overexpression of ADP speeds up the cell-to-cell spread of the virus, 33 which can enhance the anticancer efficacy of an oncolytic Ad vector.
We report that VRX-011 replicates within and efficiently lyses cancer cells, and that its replication is attenuated in noncancerous cells. VRX-011 suppresses the growth of tumor xenografts in nude mice. It produced low toxic effects after intravenous injection into C57BL/6 mice.
Results
The hTERT promoter is active in various cancer cell lines but not in primary or normal cells
To analyze hTERT promoter activity in various cell lines, plasmid phTERT-CAT was constructed from a 1672 bp hTERT promoter driving the CAT reporter gene. At 48 h after transfection, CAT activity of cells transiently transfected with phTERT-CAT was compared with cells transfected with pGL2-Basic vector (no promoter) or pCMV-CAT (positive control). pCMV b-galactosidase was used as an internal control plasmid to normalize for transfection efficacy. As shown in Figure 2a , the hTERT promoter activity was high in the cancer cell lines, namely A549, HeLa, DU145, 293-E4, SW480, and Hep3B cell lines, but it was very low or undetectable in HEL299 and human foreskin fibroblast (HFF) normal cells. These results demonstrate hTERT promoter activity in different cancer cell lines but little or no activity in the two noncancerous cell types tested.
As most primary human cells are difficult to transfect, we constructed a pair of replication-deficient Ad vectors, named AdhTERT-Luc and AdCMV-Luc, in which the luciferase gene is transcribed from the hTERT or the CMV immediate-early promoters, respectively. These vectors were used to evaluate hTERT promoter activity in primary normal human bronchial epithelial (NHBE) cells and human umbilical vein endothelial cells (HU-VEC), normal HEL299 cells, and different cancer cell lines. Expression of luciferase was analyzed 24 h post infection (p.i.). In primary NHBE, HUVEC, and normal HEL299 cells, the hTERT promoter activity was at basal level (3-4 logs lower than CMV promoter activity) (Figure 2b ), whereas it was only 1-2 orders of magnitude less than the CMV promoter activity in A549, HeLa, Hep3B, and DLD-1 cancer cells (Figure 2c ). These data demonstrate that the hTERT promoter is active in cancer cells but not in primary cells.
The hTERT promoter selectively regulates protein expression in VRX-011
To investigate whether the hTERT promoter retained its tumor-selectivity when inserted into the E4 region of VRX-011, A549 lung cancer and primary HUVEC cells were infected with 3 plaque forming units per cell (PFU/ cell) of VRX-011 or VRX-007. Cell extracts were analyzed for E1A and late proteins by immunoblot. VRX-011 and VRX-007 expressed the same level of E1A proteins (data not shown) in both cell lines, indicating the same level of infection. VRX-011 and VRX-007 also expressed the same levels of late proteins in A549 cancer cells (Figure 2d ). However, late proteins were barely detectable in VRX-011-infected HUVEC cells when compared to VRX-007 (Figure 2d ). Similar results were obtained with small airway epithelial cells (SAEC) (data not shown). Inasmuch as the expression of Ad late proteins is dependent on E4 proteins, these data indicate that the hTERT promoter directing the expression of E4 genes in VRX-011 is much more active in cancer cells than in primary cells.
VRX-011 is attenuated in primary cells
Since E4 proteins are required for Ad replication, VRX-011 should replicate well only in those cells in which the hTERT promoter is active. To test this hypothesis, A549, HUVEC, and HEL299 cells were mock-infected or infected with 3 PFU/cell of VRX-011 or VRX-007. The cells were photographed through phase-contrast microscopy at 3, 4, and 6 days p.i. for A549, HUVEC, and HEL299 cells, respectively. Both VRX-011 and VRX-007 caused severe cytopathic effect on A549 cells at 3 days Telomerase promoter-regulated oncolytic Ad vector M Kuppuswamy et al p.i. (Figure 3 ). In contrast, only VRX-007 induced cytopathic effect in primary HUVEC (at 4 days p.i.) and normal HEL299 cells (at 6 days p.i.); VRX-011 left these cells largely intact ( Figure 3 ). These data imply that the replication of VRX-011 is significantly less efficient in primary HUVEC and HEL299 cells than in A549 cells.
VRX-011 induces cell death in different cancer cells
To demonstrate that VRX-011 has an attenuated phenotype in normal cells but not in tumor cells, we tested its ability to kill six different cancer cell lines. Cells were mock-infected or infected with 20 PFU/cell of VRX-007 or VRX-011. At the time points indicated in Figure 4a , the plasma membrane integrity (cell viability) was checked by Trypan blue exclusion. Cancer cell lines HepG2, LNCaP, SW480, SW1116, LS513, and LS174T were killed efficiently by either VRX-011 or VRX-007 ( Figure 4a ). Primary HFF cells infected with VRX-011 were about 62.1 and 38.1% viable at 9 and 16 days p.i., respectively, whereas only 40% of VRX-007-infected cells were alive at 9 days p.i., and they were all killed at 16 days p.i. (Figure  4a ). We conclude from these data that VRX-011 induces only limited cytopathic effect in normal cells, but is nearly as efficient in killing assorted cancer cell lines as VRX-007.
The rate of VRX-011 replication and spread is similar to that of Ad5 in A549 cells
One way to assess the overall rate of viral replication, virus release, and reinfection is to record the rate at which plaques appear ('plaque development') on a given cell line. In this experiment, VRX-011 plaque development was compared to VRX-007 and Ad5 in A549 cells. VRX-011 formed plaques as rapidly as Ad5 (Figure 4b ), which confirms the ability VRX-011 to destroy tumor cells. The parental vector, VRX-007, spreads from cell to cell very quickly, 33 and therefore produced a steeper plaque development curve (Figure 4b ).
VRX-011 replicates well in cancer cell lines but is restricted in primary cells
To demonstrate that the tumor-selective cell killing caused by VRX-011 is due to tumor-selective replication, we compared the replication of VRX-011 to VRX-007 in selected cancer cell lines and primary human cells. A549, DU145, SW480, HUVEC, and NHBE cells were mockinfected or infected with 3 PFU/cell of VRX-011 or VRX-007. The infected cells were harvested at 4 days p.i.; by this time, virus production reached a plateau (data not shown). The virus yield was established by plaque assay in A549 cells. Both viruses gave similar yields in A549, DU145, and SW480 cells ( Figure 5 ). However, in primary NHBE and HUVEC cells, VRX-011 produced approximately 100-fold less progeny virus than its parent virus ( Figure 5 ). These results demonstrate that VRX-011 grows nearly as efficiently as VRX-007 in cancer cell lines but its replication is restricted in primary cells.
Intratumoral administration of VRX-011 suppresses the growth of subcutaneous Hep3B liver carcinoma tumor xenografts in nude mice
To further evaluate the cancer cell killing capability of VRX-011, we examined the ability of VRX-011 to control 
Intravenous administration of VRX-011 suppresses the growth of Hep3B human liver cancer xenografts in nude mice
To evaluate if the route of administration of VRX-011 influences its ability to suppress tumor growth, we injected 5 Â 10 6 Hep3B cells into both hind flanks of nude mice. When the tumors reached about 250 ml, the animals were mock-(buffer-) injected or injected intravenously (tail vein) with 3 Â 10 7 PFU (total dose) or 3 Â 10 8 PFU (total dose) of VRX-011 or VRX-007. The doses were fractionated into three daily injections. Each group contained nine animals. Both VRX-011 and VRX-007 effectively suppressed the growth of the tumors; during the experiment, the vehicle-injected tumors grew about eight-fold while the VRX-011-and VRX-007-injected tumors grew about 2.5-fold (Figure 6b ). We did not observe a dose effect (VRX-011 3 Â 10 7 PFU versus mock: P ¼ 0.027; VRX-011 3 Â 10 8 PFU versus mock: P ¼ 0.014; VRX-011 3 Â 10 7 PFU versus VRX-007 3 Â 10 7 PFU: P ¼ 0.37; VRX-011 3 Â 10 8 PFU versus VRX-007 3 Â 10 8 PFU: P ¼ 0.26). These data show that VRX-011 was as effective in suppressing tumor growth following intravenous administration as was the parental VRX-007 vector.
Intravenously administered VRX-011 reduces the number of nodules in a disseminated lung cancer model
To test whether VRX-011 can inhibit the growth of disseminated cancer in mouse lungs, we injected 2 Â 10 6 A549 cells into the tail vein of nude mice. These cells, derived from a human lung adenocarcinoma, populated the lung and formed rapidly growing tumor nodules. After the 10th day, groups of mice received PBS ++ or 6 Â 10 8 PFU (total dose) of VRX-011 or VRX-007, respectively, injected into the jugular vein. The doses were fractionated into three injections, given on three consecutive days. At 3 weeks after cell injection, lungs from each mouse were removed and stained with India ink (Figure 6c ). Each group of lungs was examined for the size and number of tumor nodules. Both VRX-007 and VRX-011 reduced the tumor nodules considerably when , and 1 Â 10 9 PFU) of VRX-011 or VRX-007 were administered by tail vein injection into C57BL/6 mice. A control group received vehicle (PBS ++ ) only. Blood was collected at 4, 7, and 14 days p.i., and ALT and AST liver enzyme levels were analyzed. In the animals injected with 1 Â 10 9 PFU of VRX-011, ALT and AST levels were marginally elevated at day 4, and returned to normal levels at 7 days p.i. (Figure 7a , only ALT data are shown; AST data were very similar). At this dose level, VRX-007 caused pronounced liver toxicity; the animals became moribund and had to be killed (Figure 7b ). At the doses of 5 Â 10 8 and 1 Â 10 8 PFU of VRX-011 or VRX-007, the AST and ALT enzymes levels were the same as the control group, indicating little or no toxicity induced by VRX-011 or VRX-007. The animal weights did not change significantly during the course of the study by VRX-011 (any dose level) and VRX-007 (the two lower dose levels) (data not shown). These results indicate that VRX-011 induces minimal liver toxicity in C57BL/6 mice.
Discussion
We have constructed VRX-011, a vector with selective enhanced oncolytic activity in a wide range of tumors. VRX-011 has the E4 promoter substituted with the hTERT promoter, and it overexpresses ADP due to the deletion of most of the other E3 genes. 33 We have used the À1672 to 0 fragment (core promoter plus upstream regions) of the hTERT promoter; this fragment was shown to retain strict regulation in normal cells, while shorter versions did not. 40 Most laboratories that have applied the hTERT promoter to regulate gene expression in Ad vectors have used only the core hTERT promoter. This might lead to unrestricted replication in some cases; the hTERT core promoter (284 bp) driving the E4 genes failed to restrict the replication of an oncolytic Ad vector in telomerase-negative cells. 29 The 1672 bp hTERT promoter utilized by us might have more regulatory regions that may enhance specificity. Consistent with this hypothesis, the CAT and luciferase reporter genes were expressed by the 1672 bp hTERT promoter in a wide range of tumor cell lines, but their expression was tightly restricted in primary and normal human cells (Figure  2a-c) . We deliberately put the emphasis on maintaining strict regulation as opposed to achieving high activity, as we have demonstrated earlier that E4 proteins are not needed in great abundance for Ad replication. 8, 9 As tissue-or tumor-restricted promoters often lose their specific regulation in the context of Ad genomes, it is noteworthy that we have shown that with VRX-011, viral late proteins were expressed in lung cancer cells but not in primary endothelial cells (Figure 2d ). As Ad late proteins are expressed only in the late phase of infection, that is, after the replication of the viral genome, this means that the replication of the vector is blocked in the early phase of infection, which is what one would expect in the absence of E4 proteins. As predicted from the lack of late protein expression, VRX-011 displays an attenuated phenotype on primary and normal human cells: viral yields were 100-fold less in primary HUVEC and NHBE cells compared to its parent virus VRX-007 ( Figure 5 ). Importantly, VRX-011 is almost as potent in killing most cancer cell lines as its parental vector, VRX-007: in a single-step growth curve assay, VRX-011 had the same growth characteristic as Ad5 and VRX-007 in cancer cells ( Figure 5 ). Taken together, these data indicate that VRX-011 causes much more cytopathic effect in cancer cells than in noncancerous cells due to its near wt replication in the former and restricted replication in the latter.
Next, we tested the antitumor activity of VRX-011 in a nude mouse human tumor xenograft animal model. Several genetically modified Ad vectors have been tested in different human cancer cell lines. 3, 41, 42 Many of the vectors replicate less efficiently than wt Ad5 in most tumor cell lines because the features that restrict vector Telomerase promoter-regulated oncolytic Ad vector M Kuppuswamy et al growth in normal cells result in an attenuated phenotype in cancer cells as well. We anticipated that VRX-011 would perform well in tumor experiments due to its two important features, ADP overexpression and the regulation of the low-abundance E4 genes.
When subcutaneous Hep3B tumors in nude mice were injected intratumorally with VRX-011, the growth of tumors was significantly suppressed (Figure 6a) . We observed similar reduction in the growth rate of subcutaneous Hep3B tumors after systemic delivery of VRX-011 (Figure 6b) . In a different model, the number of disseminated A549 lung tumor nodules was greatly reduced after intravenous administration of VRX-011 (Figure 6c) . In all three experiments, VRX-011 provided approximately the same level of tumor suppression as its parental vector, VRX-007. The observation that VRX-011 has similar antitumor activity as VRX-007 in animal experiments was not unexpected, as VRX-011 showed only slightly decreased replication and cytopathic effect compared to VRX-007 in a wide range of tumor cells. These data imply that VRX-011 has very robust antitumor activity, independent of the delivery route.
Safety is another important question regarding the clinical use of an oncolytic Ad vector. The tissue culture experiments discussed above indicate that VRX-011 has an attenuated phenotype in nontumorous cells. To test the toxicity of VRX-011 in vivo, C57BL/6 mice were injected with either VRX-011 or the parental VRX-007. Earlier research by other groups, for example, Jakubczak et al 43 indicated that although mice are not permissive for human Ads, intravenous injection of an oncolytic Ad results in liver toxicity in these animals. 43 With VRX-011, most encouragingly, a high dose of 1 Â 10 9 PFU caused only a slight elevation of serum ALT and AST levels at day 4 that returned to normal levels at 7 and 14 days post-treatment. Two lower doses, 5 Â 10 8 and 1 Â 10 8 PFU, did not cause detectable liver toxicity ( Figure  7a ). These data show that VRX-011 displays lower liver toxicity than its parental virus in C57BL/6 mice.
Our premise when designing VRX-011 was that most cells in a healthy adult human are telomerase negative. Although the hTERT promoter is silent in the majority of somatic cells, some types of human normal cells, such as lymphocytes, 44 CD34+ hematopoietic progenitor cells, 45, 46 and keratinocytes, 47, 48 display telomerase activity. Activation of telomerase activity in these cell lines is not well understood. Since these cells are not of epithelial origin and express low levels of the coxsackie-Ad receptor (CAR), VRX-011 (and other vectors derived from Ad5) will have difficulty in infecting them. 49, 50 Furthermore, VRX-011 contains another safety feature: it lacks the E3 proteins that counteract the host immunosurveillance. 51 Thus, in case of accidental systemic vector dissemination, the host immune response would be expected to eliminate the vector. These two 'safety' characteristics of VRX-011, the tropism for epithelial cells and the E3 deletion, should decrease the risk of extensive vector replication in these populations of telomerasepositive cells.
Summarizing our data, VRX-011 replicated well in various cancer cell lines but replicated minimally in noncancerous cells. It demonstrated robust antitumor activity against both localized and disseminated tumors following either intratumoral or intravenous administration of the vector. It showed low hepatotoxicity in mice.
From these data, we conclude that VRX-011 appears to be a possible candidate for treating a wide range of cancers.
Materials and methods

Cell lines
Human cancer cell lines A549 (alveolar carcinoma), HeLa (cervical epithelioid carcinoma), DU145 (prostate carcinoma), Hep3B (hepatocellular carcinoma), SW480 (colon carcinoma), and MCF-7 (human breast cancer) were obtained from the American Type Culture Collection (ATCC, Bethesda, MD, USA). Human embryo kidney 293 (HEK-293, 293) cells were obtained from Microbix (Toronto, ON, Canada). 293-E4 (VK10-9) cells are 293 cells that, in addition to the Ad5 E1A and E1B proteins, express Ad E4 proteins as well as the Ad protein pIX.
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HEL299 (human diploid lung fibroblast) cells were from ATCC, and were grown in DMEM containing 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 1 mM sodium pyruvate (Sigma, St Louis, MO, USA), and 0.1 mM nonessential amino acids (Sigma). A549, DU145, Hep3B, HEK-293, 293-E4, and MCF-7 cells were cultured in DMEM (Gibco, Carlsbad, CA, USA) containing 10% FBS. SW480 cells were cultured in L15 medium (Gibco) supplemented with 10% FBS. NHBE cells, HUVEC, and human primary SAEC were obtained and grown in specific medium from Cambrex (Walkersville, MD, USA). HFF cells were from Washington University (St Louis, MO, USA).
Construction of the VRX-011 vector
A 1672 bp fragment of the human TERT promoter was amplified from normal male genomic DNA from human placenta (Sigma) with a set of primers with a terminal EcoRV restriction enzyme site by use of the Fail Safe PCR amplification kit (Epicenter, Madison, WI, USA) (forward primer sequence 5 0 GCGATATCATCAGCTTTTCAAAGA CA; reverse primer sequence 5 0 GCGATATCAGCGCTGC CTGAAACTCGCGC). The amplified hTERT PCR fragment was cloned into the EcoRV site of the pBS.SK+ (Stratagene, La Jolla, CA, USA) plasmid and the cloned fragment was sequenced. The sequence of the promoter fragment differed from the published hTERT promoter sequence at two nucleotides (both C versus T), one at the À372 and another at the À577 nucleotide position (relative to transcription initiation site); these changes do not affect any consensus transcription factor binding motifs. 35 The hTERT fragment was transferred to the pdlE4prom plasmid, replacing the E4 promoter in correct orientation to drive transcription of the E4 region (pdlE4hTERT). The plasmid pdlE4prom was described earlier. 8 Cotransfections of DNA from the Ad5 E3 deletion mutant dl327 36 digested with SpeI and EcoRI together with the pdlE4hTERT plasmid into 293-E4 cells generated VRX-011 viral plaques by a process of homologous recombination. An isolate with the correct genome structure was propagated and characterized as described earlier. 9 The vector stocks were dialyzed against a physiological buffer and titered by plaque assay on 293 and A549 cells. Titers of different preparations varied from 2 Â 10 10 to 10 11 PFU/ml. The construction of the VRX-007 vector was described elsewhere 33 (see Figure 1b) . VRX-007 is considered as the Telomerase promoter-regulated oncolytic Ad vector M Kuppuswamy et al parental virus for VRX-011; the only difference between the two Ad vectors is that VRX-011 has the wt E4 promoter replaced by the hTERT promoter, while VRX-007 has wt E4 promoter (Figure 1 ).
Construction of pTERT.CAT
Plasmid pTERT.CAT was constructed by cloning the hTERT DNA fragment into the pGL2-Basic reporter plasmid (Promega, Madison, WI, USA) in such a manner that it directs the transcription of the CAT gene.
Construction of AdTERT-Luc
The EcoRV digested hTERT promoter fragment from the pBS.SK+hTERT plasmid was inserted into the EcoRV site of plasmid p722 (p722-hTERT). The p722 plasmid contains the SspI-Bst1107 I A fragment of pDE1sp1A (Microbix) cloned between the SspI and PvuII sites of pBS.SK+ (Stratagene). This plasmid is similar to pDE1-sp1A but it replicates to a higher copy number. The luciferase fragment from plasmid pGL3 (Promega) was isolated after NcoI and BamHI digestion and was bluntended. The blunt-ended luciferase fragment was inserted in the correct orientation into the blunt-ended HindIII site of plasmid p722-hTERT (p722-hTERT-Luc). HEK-293 cells were cotransfected with plasmids p722-hTERT-Luc and pBHGKD3E3. Plasmid pBHGKD3E3 was constructed as follows. The SpeI-NdeI fragment containing the E3 region of KD3 37 was used to substitute for the corresponding SpeI-NdeI fragment in pBHG10 (Microbix). Plaques consisting of the AdhTERT-Luc recombinant virus were plaque-purified twice and expanded into a virus stock in 293 cells. This stock yielded a titer of 6.9 Â 10 8 PFU/ml in 293 cells and was stored at À801C.
Construction of AdCMV-Luc
The luciferase fragment from plasmid pGL3 was cleaved at the unique NcoI site, then blunt ended and digested with BamHI. The luciferase fragment was inserted in the correct orientation between the blunt-ended HindIII and BamHI sites of pcDNA3.1 vector (pcDNA3.1-Luc). The CMV-luciferase fragment was excised from pcDNA3.1-Luc by BglII and BamHI digestion, blunt-ended, and inserted into the EcoRV site of plasmid p722 to give the p722-CMV-Luc construct. The AdCMV-Luc virus was generated, purified, and titered as the AdTERT-Luc virus, reaching a titer of 6.8 Â 10 8 PFU/ml on 293 cells.
CAT assay
Expression of the CAT (chloramphenicol acetyltransferase) reporter gene was determined in cells transfected with 2 mg of CAT reporter plasmid constructs and 0.5 mg of pCMV-b-galactosidase control plasmid 48 h after transfection with a CAT ELISA kit (Roche Diagnostics, GmbH, Mannheim, Germany). A b-galactosidase assay was also carried out with the same extracts to standardize for transfection efficiency.
Luciferase assay
Cells were infected with Ad vectors at 10 PFU/cell. At 24 h p.i., the cells were harvested and the cell extracts were analyzed using the Luciferase Reporter Gene System (Promega, Madison, WI, USA) in a Wallac 1420 Victor Multilabel Counter luminometer, according to the manufacturer's protocol. All experiments were repeated three times in triplicate.
Plaque development assay
Viruses were analyzed in a standard plaque assay on A549 cells as outlined by Tollefson et al. 38 The number of plaques seen on a given day of the experiment (X-axis) was plotted as a percentage of plaques seen on the final day of the experiment (Y-axis).
Single-step growth curve A549, DU145, SW480, NHBE, and HUVEC cells of 50-60% confluency were mock-infected or infected with 3 PFU/cell of VRX-011 or VRX-007. The cells and the medium were harvested at 4 days p.i. and virus yield was determined by plaque assay on A549 cells as described earlier. 9 
Cell viability assay
Cells were infected at 20 PFU/cell with different Ad vectors. At the indicated times, a Trypan blue exclusion assay was carried out as described previously. 31 For each data point, about 400 cells were examined and the percentage of blue cells was calculated.
Immunoblots
Cells were mock-infected or infected with viruses at 3 PFU/cell. At 1 and 2 days p.i., cells were harvested, proteins were extracted, and Ad late or E1A proteins were detected by immunoblot using an antiserum against Ad virions, as described earlier. 9 
Subcutaneous tumor model
All mice were cared for and treated according to the Guide for the Care and Use of the Laboratory Animals and the institutional guidelines of Saint Louis University. For the evaluation of intratumoral efficacy of vectors, 5-6-week-old female nude mice (Harlan Sprague Dawley, Indianapolis, IN, USA) were inoculated subcutaneously into both hind flanks with about 7 Â 10 6 Hep3B cells to establish subcutaneous tumors. After the tumor volume reached about 400 ml, the animals were injected intratumorally with 50 ml of vehicle (phosphate-buffered saline with 1 mM MgCl 2 and 1 mM CaCl 2 (PBS ++ )) alone or with 3 Â 10 8 PFU of VRX-011 or VRX-007 in 50 ml of vehicle, for three consecutive days (9 Â 10 8 PFU total). Each group contained nine animals. Tumor sizes were measured twice weekly using computer-linked digital calipers (Silvac, Switzerland). Tumor volumes were calculated with an in-house developed software (Mouser). The significance of the results was examined by oneway ANOVA, and pair-wise comparisons were made with Student's t-test.
The efficacy of the vectors following intravenous injection was also studied. Female 5-6-week-old nude mice (nine animals per group) were injected subcutaneously with 5 Â 10 6 Hep3B cells into both hind flanks. When the tumors reached about 250 ml, mice were injected intravenously (into the tail vein) with 100 ml of vehicle or 3 Â 10 7 or 3 Â 10 8 PFU of VRX-011 or VRX-007 in 100 ml of vehicle, respectively. The doses were fractionated into three daily injections. Tumors were measured twice weekly and the data were analyzed using the Mouser software.
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